1 terminated. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Terminated 1 |
Follow EDP-305: new trials by email Literature Review of EDP-305 trials Research Report on EDP-305
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Randomized, Double-blind Study to Assess the Safety and Efficacy of EDP-305 in Subjects With Liver-biopsy Proven NASH EDP-305 1.5 mg, EDP-305 2 mg, Placebo - Non-Alcoholic Steatohepatitis | Phase 2 | Terminated | Enanta Pharmaceuticals, Inc | 98 | 2020-01-27 | 2023-05-19 |
Fatty Liver (1) · Non-alcoholic Fatty Liver Disease (1)
Enanta Pharmaceuticals, Inc (1)
Argentina (1) · Canada (1) · Germany (1) · Puerto Rico (1) · United Kingdom (1) · United States (1)
2019 (1)